Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCA effects on lipoprotein metabolism in PBC
NCT01865812Phase 2Completed
- Sponsor
- Intercept Pharmaceuticals
- Start
- Dec 2013
- Primary completion
- Aug 2014
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of obeticholic acid in primary biliary cholangitis (PBC), sponsored by Intercept Pharmaceuticals. Started Dec 2013; status: completed.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT01865812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01865812.